Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer
- Focus Biomarker; Therapeutic Use
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2019 as reported by ClinicalTrials.gov.
- 20 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2019 as reported by ClinicalTrials.gov.